We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Respiratory Medicine

Journal Scan / Research · January 27, 2021

Efficacy and Safety of Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease Treated With Mycophenolate

The Lancet Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Efficacy and Safety of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Mycophenolate: A Subgroup Analysis of the SENSCIS Trial
Lancet Respir Med 2021 Jan 01;9(1)96-106, KB Highland, O Distler, M Kuwana, Y Allanore, S Assassi, A Azuma, A Bourdin, CP Denton, JHW Distler, AM Hoffmann-Vold, D Khanna, MD Mayes, G Raghu, MC Vonk, M Gahlemann, E Clerisme-Beaty, M Girard, S Stowasser, D Zoz, TM Maher,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading